Conference Presentations

2016

ASH 2016 Poster (2)

TCA Cycle Inhibition by CPI-613® Increases Sensitivity to Chemotherapy in Older and Poor Risk Acute Myeloid Leukemia (AML)

Learn More
2015

ASCO 2015 Poster

The Mitochondrial Metabolism Inhibitor CPI-613® in Combination with High Dose Ara-C (HDAC) and Mitoxantrone is Highly Active in High Risk Relapsed or Refractory AML.

Learn More

ASH 2015 Poster

The Mitochondrial Metabolism Inhibitor CPI-613® in Combination with High Dose Ara-C (HDAC) and Mitoxantrone is Highly Active in Poor Risk Relapsed or Refractory Acute Myeloid Leukemia (AML).

Learn More
2014

ASCO 2014 Poster

A phase I Study of the Mitochondrial Metabolism Inhibitor CPI-613® in Combination with High Dose Ara-C and Mitoxantrone for Relapsed or Refractory Acute Myeloid Leukemia

Learn More
2013

ASCO 2013 Poster

A Phase I Study of the First in Class Mitochondrial Metabolism Inhibitor CPI-613® in Patients with Advanced Hematologic Malignancies

Learn More
2012

ASCO 2012 Poster (1)

Translational Assessment of the Efficacy of CPI-613® Against Pancreatic Cancer in Animal Models Vs. Patients With Stage IV Disease

Learn More

AACR 2012 Poster (1)

Lipoic acid analogs induces ROS, leading to potent mitochondrial enzyme inhibition, metabolic dysfunction and cell death in tumor cells

Learn More

AACR 2012 Poster (2)

Regulation of Pancreatic, Gliosarcoma, and Non-Small Lung Cancer via CPI-613®, a Novel Selective Anticancer Therapeutic Agent

Learn More
2011

AACR 2011 Poster

Poster: Potent anti-cancer agents, non-redox-active lipoate derivatives, have pervasive, catastrophic regulatory effects on cancer cell metabolism

Learn More